• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Health Sciences Acquisitions Corporation 2

    2/6/23 4:37:12 PM ET
    $HSAQ
    Medical/Dental Instruments
    Health Care
    Get the next $HSAQ alert in real time by email
    SC 13G 1 mdt20230203_sc13g.htm SCHEDULE 13G mdt20230203_sc13g.htm

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

     

    Orchestra BioMed Holdings, Inc.

    (Name of Issuer)

     

    Common Stock, Par Value $0.0001 Per Share

    (Title of Class of Securities)

         
     

    68572M106

     
     

    (CUSIP Number)

     
         
     

    January 26, 2023

     
     

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

     

    ☐

    Rule 13d-1(b)

     

    ☒

    Rule 13d-1(c)

     

    ☐

    Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Page 1 of 6 Pages

     

     

    SCHEDULE 13G

    CUSIP No. 68572M106

     

    Page 2 of 6 Pages

     

    1

    names of reporting persons

     

    Medtronic plc

    2

    check the appropriate box if a member of a group (see instructions)*         

     

    (a) ☐

    (b) ☐

       

    3

    sec use only

       

    4

    citizenship or place of organization

     

    Ireland

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    sole voting power

     

    0

    6

    shared voting power

     

    4,999,423

    7

    sole dispositive power

     

    0

    8

    shared dispositive power

      4,999,423

    9

    aggregate amount beneficially owned by each reporting person

     

    4,999,423

    10

    check if the aggregate amount in row (9) excludes certain shares (see instructions)         

       ☐

    11

    percent of class represented by amount in row (9)

     

    15.8% (1)

    12

    type of reporting person (see instructions)

     

    OO

     

     

    (1)

    Calculated based on 31,614,079 shares of Common Stock issued and outstanding as of January 26, 2023, as reported in the Issuer’s Current Report on Form 8-K filed January 31, 2023.

     

     

     

     

    CUSIP No. 68572M106

     

    Page 3 of 6 Pages

     

    1

    names of reporting persons

     

    Covidien Group S.a.r.l.

    2

    check the appropriate box if a member of a group (see instructions)*         

     

    (a) ☐

    (b) ☐

       

    3

    sec use only

       

    4

    citizenship or place of organization

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    sole voting power

     

    0

    6

    shared voting power

     

    4,999,423

    7

    sole dispositive power

     

    0

    8

    shared dispositive power

     

    4,999,423

    9

    aggregate amount beneficially owned by each reporting person

     

    4,999,423

    10

    check if the aggregate amount in row (9) excludes certain shares (see instructions)         

       

    11

    percent of class represented by amount in row (9)

     

    15.8% (1)

    12

    type of reporting person (see instructions)

     

    OO

     

     

    (1)

    Calculated based on 31,614,079 shares of Common Stock issued and outstanding as of January 26, 2023, as reported in the Issuer’s Current Report on Form 8-K filed January 31, 2023.

     

     

     

     

    Item 1(a)

    Name of Issuer:

     

    Orchestra BioMed Holdings, Inc.

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices:

     

    150 Union Square Drive

    New Hope, Pennsylvania 18938

     

    Item 2(a)

    Name of Persons Filing:

     

    Medtronic plc

     

    Covidien Group S.a.r.l.

     

    Item 2(b)

    Address of Principal Business Office or, if None, Residence:

     

    Medtronic plc: 20 On Hatch, Lower Hatch Street, Dublin 2, Ireland

     

    Covidien Group S.a.r.l.: 3b, Bd. Prince Henri, 4th Floor L-1724 Luxembourg

     

    Item 2(c)

    Citizenship:

     

    Medtronic plc: Ireland

     

    Covidien Group S.a.r.l.: Luxembourg

     

    Item 2(d)

    Title of Class of Securities:

     

    Common Stock, Par Value $0.0001 Per Share

     

    Item 2(e)

    CUSIP Number: 68572M106

     

    Item 3

    If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

     

    (a)

    ☐     Broker or dealer registered under Section 15 of the Act.

     

    (b)

    ☐     Bank as defined in Section 3(a)(6) of the Act.

     

    (c)

    ☐     Insurance company as defined in Section 3(a)(19) of the Act.

     

    (d)

    ☐     Investment company registered under Section 8 of the Investment Company Act of 1940.

     

    (e)

    ☐     An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E).

     

    (f)

    ☐     An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F).

     

    (g)

    ☐     A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).

     

    (h)

    ☐     A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.

     

    (i)

    ☐     A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.

     

    Page 4 of 6 Pages

     

     

     

    (j)

    ☐     A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k)

    ☐     Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4

    Ownership

     

    See Cover Pages, Items 5 through 11.

     

    Item 5

    Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

     

    Item 6

    Ownership of More than Five Percent on Behalf of Another Person:

     

    Not applicable.

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:

     

    Not applicable.

     

    Item 8

    Identification and Classification of Members of the Group:

     

    Not applicable.

     

    Item 9

    Notice of Dissolution of Group:

     

    Not applicable.

     

    Item 10

    Certifications:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Exhibits

    Joint Filing Agreement between Medtronic plc and Covidien Group S.a.r.l., dated as of the date hereof and filed as Exhibit 1 to this Schedule 13G, which is incorporated herein by reference.

     

    Page 5 of 6 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:  February 6, 2023

    Medtronic plc

     

     

    /s/ Martha Ha                                             

    Name: Martha Ha

    Title: Vice President and Assistant Secretary

       
       
       
       

    Dated:  February 6, 2023

    Covidien Group S.a.r.l.

     

     

    /s/ Erik De Gres                                    

    Name: Erik De Gres

    Title: General Manager

     

    Page 6 of 6 Pages

     

     

    EXHIBIT 1

     

     

    JOINT FILING AGREEMENT

     

    In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13G to which this joint filing agreement is attached, along with any amendments thereto that may be required, and have duly executed this joint filing agreement as of the date set forth below.

     

     

     

    Dated: February 6, 2023

     

    Medtronic plc

       
       
        /s/ Martha Ha
       

    Name: Martha Ha

       

    Title:   Vice President and Assistant Secretary

       
       

    Dated: February 6, 2023

     

    Covidien Group S.a.r.l.

       
       
        /s/ Erik De Gres
       

    Name: Erik De Gres

       

    Title:   General Manager

     

     
    Get the next $HSAQ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSAQ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HSAQ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Orchestra BioMed Debuts as Nasdaq-Traded Company with Lead Programs Targeting Hypertension and Artery Disease and Novel Partnership-Enabled Business Model

    Business combination with Health Sciences Acquisitions Corporation 2, a special purpose acquisition company sponsored by an affiliate of RTW Investments, LP, completed on January 26, 2023 The combination was announced simultaneously with Orchestra's strategic collaboration with Medtronic to develop BackBeat Cardiac Neuromodulation Therapy™ as potential integrated hypertension treatment for cardiac pacemaker patients Gross proceeds from transaction and previously completed financing led by RTW and Medtronic total approximately $180 million and support cash runway into 2026 Orchestra BioMed Holdings, Inc. to commence trading on January 27 on Nasdaq Global Market under ticker symbol "OBIO"

    1/27/23 8:00:00 AM ET
    $HSAQ
    Medical/Dental Instruments
    Health Care

    Orchestra BioMed™ Announces Presentation of Positive Long-Term Clinical Results from MODERATO II Control Patients Crossover Extension Study of BackBeat CNT™ at TCT 2022

    NEW HOPE, Pa., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Orchestra BioMed™, Inc., ("Orchestra BioMed" or the "Company"), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies, today announced the presentation of positive long-term clinical results from the MODERATO II Control Patients Crossover Extension Study of BackBeat Cardiac Neuromodulation Therapy™ ("BackBeat CNT") at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 annual conference being held in Boston, MA. BackBeat CNT is a bioelectronic therapy candidate that is compatible with standard pacemakers and designed to lower bloo

    9/20/22 8:00:00 AM ET
    $HSAQ
    Medical/Dental Instruments
    Health Care

    Orchestra BioMed™ Announces Strategic Collaboration, Closing of $110 Million Private Equity Financing and Plans to List on Nasdaq Through Merger with Health Sciences Acquisitions Corporation 2

          Strategic collaboration with Medtronic to develop BackBeat Cardiac Neuromodulation Therapy™ as potential integrated hypertension treatment for cardiac pacemaker patients Investors in $110 million Series D financing include Medtronic and Terumo as well as lead investor RTW Investments and founding investor Perceptive Advisors Business combination with Health Sciences Acquisitions Corporation 2 (NASDAQ:HSAQ) (the "Business Combination"); upon closing, the common stock of the combined company is expected to be listed on Nasdaq under the ticker symbol "OBIO"; Business Combination is supported by $20 million in total forward purchase agreements and an up to $50 million backstop agreement

    7/5/22 8:00:00 AM ET
    $HSAQ
    Medical/Dental Instruments
    Health Care

    $HSAQ
    SEC Filings

    View All

    Health Sciences Acquisitions Corporation 2 filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

    11/27/23 7:03:05 PM ET
    $HSAQ
    Medical/Dental Instruments
    Health Care

    Health Sciences Acquisitions Corporation 2 filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

    11/14/23 6:02:31 AM ET
    $HSAQ
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Health Sciences Acquisitions Corporation 2

    10-Q - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

    11/13/23 4:10:53 PM ET
    $HSAQ
    Medical/Dental Instruments
    Health Care

    $HSAQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 5 filed by Medtronic Plc

    5 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    2/14/24 6:37:19 PM ET
    $HSAQ
    Medical/Dental Instruments
    Health Care

    New insider Papandreou George claimed ownership of 20,000 shares (SEC Form 3)

    3 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    9/29/23 8:33:45 PM ET
    $HSAQ
    Medical/Dental Instruments
    Health Care

    SEC Form 3: New insider Orchestra Biomed Holdings, Inc. claimed ownership of 804,096 shares

    3 - Orchestra BioMed Holdings, Inc. (0001814114) (Reporting)

    9/22/23 4:17:17 PM ET
    $HSAQ
    Medical/Dental Instruments
    Health Care

    $HSAQ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Health Sciences Acquisitions Corporation 2 (Amendment)

    SC 13G/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

    2/14/24 4:49:07 PM ET
    $HSAQ
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Health Sciences Acquisitions Corporation 2 (Amendment)

    SC 13G/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

    2/14/24 4:03:46 PM ET
    $HSAQ
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Health Sciences Acquisitions Corporation 2

    SC 13G - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

    2/14/24 10:03:05 AM ET
    $HSAQ
    Medical/Dental Instruments
    Health Care